Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer
Compass Therapeutics announces a webcast to reveal topline secondary endpoints from its Phase 2/3 COMPANION-002 clinical study evaluating tovecimig combined with paclitaxel for advanced biliary tract cancer. The webcast is scheduled for April 27, 2026, presenting data on the bispecific antibody's efficacy and safety profile.